Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27602765 | 0.85 | NLRP3 (0.45) | LMNAHSD17B10KDM4EALDH1A1 | |
| SCHEMBL15516922 | 0.84 | MMP1 (0.48) | MMP1MMP9MMP8LMNAHSD17B10 | |
| SCHEMBL6165860 | 0.82 | HSD17B10 (0.56) | HSD17B10TSHRALOX15KMT2AKDM4E | |
| SCHEMBL3681218 | 0.82 | HSP90AB1 (0.47) | MMP1MMP9MMP8LMNAHSD17B10 | |
| SCHEMBL15516697 | 0.81 | KMT2A (0.56) | MMP1MMP9MMP8LMNAHSD17B10 | |
| SCHEMBL4677835 | 0.81 | MMP1 (0.46) | MMP1MMP9MMP8LMNAHSD17B10 | |
| SCHEMBL15517469 | 0.81 | LMNA (0.53) | MMP1MMP9MMP8LMNAHSD17B10 | |
| SCHEMBL15517570 | 0.80 | OGG1 (0.53) | LMNAHSD17B10TSHRALOX15KMT2A | |
| SCHEMBL11334052 | 0.79 | MMP1 (0.45) | MMP1MMP9MMP8LMNAHSD17B10 | |
| SCHEMBL13008090 | 0.79 | LMNA (0.46) | LMNAHSD17B10ALOX15KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2890677-B1 | N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2017-11-15 | — | — | EP | disclosed |
| US-9447083-B2 | N-acylhydrazone derivatives for selective T cell inhibitor and anti-lymphoid malignancy drug | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2016-09-20 | — | — | US | disclosed |
| US-20150252030-A1 | N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-09-10 | — | — | US | disclosed |
| EP-2890677-A1 | N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG | Chong Kun Dang Pharmaceutical Corp. (KR) | 2015-07-08 | — | — | EP | disclosed |
| CN-104755460-A | N-acylhydrazone derivatives for selective T cell inhibitor and anti-lymphoid malignancy drug | CHONG KUN DANG PHARM CORP | 2015-07-01 | — | — | CN | disclosed |
| WO-2014035149-A1 | N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2014-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252030-A1 | N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG | MALT1, MCL1, ACIN1 | MMP1 2196/4885MMP9 2142/4885MMP8 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.